To Determine the Food Effect and Bioavailability of Three Formulations of Veliparib in Subjects With Solid Tumors
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
A Phase 1, Single-Dose, Randomized, Group Sequential Cross-Over Study Evaluating the Bioavailability and Food Effect of Three Formulations of Veliparib on Pharmacokinetics in Subjects With Solid Tumors
Assess the oral bioavailability of veliparib [ Time Frame: Up to 4 weeks. ]
Assess the relative bioavailability of Formulation A, Formulation B and Formulation C with or without food measured using area under the plasma concentration-time curve (AUC), the maximum observed plasma concentration (Cmax), and time to Cmax (Tmax).
Secondary Outcome Measures
To evaluate the safety and tolerability of veliparib in patients with solid tumors [ Time Frame: Up to 4 weeks ]
Safety and tolerability will be assessed through clinical laboratory tests, electrocardiograms (ECGs), vital signs, physical exams and adverse event assessments
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Subjects with cytologically/histologically confirmed solid tumors that are either relapsed or refractory to standard therapy or there is no known effective therapy.
In the opinion of the Investigator, life expectancy is 12 weeks or greater.
Subjects with known brain metastases must have clinically controlled neurologic symptoms, defined as surgical excision and/or radiation therapy followed by 21 days of stable neurologic function and no evidence of central nervous system (CNS) disease progression as determined by computed tomography (CT) scan or magnetic resonance imaging (MRI) within 21 days prior to the first dose of study drug.
Subject has an Eastern Cooperative Oncology Group (ECOG) performance score of 0 to 2.
Subject must have adequate bone marrow, renal and hepatic function per local laboratory reference range.
The subject is unable to swallow capsules or has nausea or vomiting.
Female subject is pregnant or breast-feeding.
Subject has a history of or an active medical condition(s) that affects absorption or motility (e.g., Crohn's disease, celiac disease, gastroparesis, short bowel syndrome).
History of gastric surgery, vagotomy, bowel resection (except for left hemicolectomy) or any surgical procedure that might interfere with gastrointestinal motility, potentiometric hydrogen ion concentration (pH) or absorption.
Subject exhibits evidence of other clinically significant uncontrolled condition(s) including, but not limited to:
Known seizure disorder that is uncontrolled over the past month
Active uncontrolled infection
Unstable angina pectoris or cardiac arrhythmia
Psychiatric illness/social situation that would limit compliance with study requirements